Research
Hormonal
GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.
Consider GLP-1 receptor agonists for patients at high risk of cardiovascular issues or renal failure.
StrongSupportsmedium confidence
Large-scale randomized, controlled trials have shown that GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.
Why this rating
Supported by large-scale randomized, controlled trials.
Source
GLP-1 Receptor Agonists
Clifford J. Rosen et al. · New England Journal of Medicine · 2026
reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →